Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma

Shi-Long Zhang; Lei Chen; Lin-Lin Bu; Zi-Li Yu; Si-Rui Ma

doi:10.3390/biomedicines11102718

Identification of SEC61G as a Diagnostic and Prognostic Biomarker in Oral Squamous Cell Carcinoma

Biomedicines. 2023 Oct 6;11(10):2718. doi: 10.3390/biomedicines11102718.

Authors

Shi-Long Zhang^{1

2}, Lei Chen¹, Lin-Lin Bu^{1

3}, Zi-Li Yu^{1

3}, Si-Rui Ma^{1

3}

Affiliations

¹ State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
² Department of Oral and Maxillofacial Surgery, Dongfeng Stomatological Hospital, Hubei University of Medicine, Shiyan 442000, China.
³ Department of Oral and Maxillofacial-Head and Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.

Abstract

Oral squamous cell carcinoma (OSCC) is a heterogeneous malignancy originating from the oral mucosal epithelium. Detecting novel biomarkers can offer crucial information on disease aggressiveness and expected clinical outcomes for individual patients. SEC61G, an aberrantly expressed gene in various cancers, has been associated with negative clinical outcomes. However, its expression and clinical significance in OSCC is still unclear. In the present study, we investigated the SEC61G expression level in OSCC using bioinformatic and immunohistochemical analyses. Additionally, our findings revealed a significant correlation between SEC61G expression and clinicopathological characteristics, as well as a worse prognosis in OSCC patients. Notably, flow cytometry analysis on patient samples revealed that SEC61G expression was also linked to decreased immune infiltration in OSCC patients. In conclusion, our study provides evidence supporting SEC61G's role as a potential diagnostic, prognostic, and therapeutic marker in OSCC.

Keywords: SEC61G; immune infiltration; oral squamous cell carcinoma; prognosis.

Grants and funding

This work was supported by the National Natural Science Foundation of China from Z.-L.Y. (funding number: 81801842) and S.-R.M. (funding number: 81802715).